uniQure NV QURE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
UniQure Shares Soar on Go-to-Market Plan
-
UniQure to Seek FDA Approval to Market Huntington's Disease Drug
-
This biotech's stock soared after a 'polarizing' FDA official is stepping down
-
UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short
-
UniQure Climbs on Scheduling FDA Meeting for Huntington's Disease Treatment
-
UniQure Shares Drop After More Negative News From FDA on Huntington's Disease Drug
-
UniQure Shares Sink After Negative FDA Response to Huntington's Disease Treatment
-
Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 68.75M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 132.75
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 221
- Website
- https://www.uniqure.com
Valuation
|
Metric
|
QURE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 16.92 |
Price/Sales | 132.75 |
Price/Cash Flow | — |
Price/Earnings
QURE
Financial Strength
|
Metric
|
QURE
|
|---|---|
Quick Ratio | 9.97 |
Current Ratio | 10.40 |
Interest Coverage | −2.63 |
Quick Ratio
QURE
Profitability
|
Metric
|
QURE
|
|---|---|
Return on Assets (Normalized) | −28.28% |
Return on Equity (Normalized) | −171.62% |
Return on Invested Capital (Normalized) | −94.61% |
Return on Assets
QURE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|S@p@<<S | LOCK|cZ>y | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&wwB!f | LOCK|rlZwT | $71B | |||
| argenx SE ADR
ARGX
| LOCK|w^PhK& | LOCK|Dh | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%h$#yNY | LOCK|vy | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^#>dJVv | LOCK|sGsP^ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^$bM>@J! | LOCK|?KH@f | $26B | |||
| Moderna Inc
MRNA
| LOCK|#K%#?Dh | LOCK|kjG | $24B | |||
| Incyte Corp
INCY
| LOCK|#N#>@s | LOCK|zm$ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|#?W^^h | LOCK|CrY | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|@Y@XCP | LOCK|J> | $16B |
United States